AD57

CAS No. 1093380-42-7

AD57( —— )

Catalog No. M33828 CAS No. 1093380-42-7

AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 90 In Stock
2MG 32 In Stock
5MG 79 In Stock
10MG 148 In Stock
25MG 250 In Stock
50MG 351 In Stock
100MG 476 In Stock
200MG 644 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AD57
  • Note
    Research use only, not for human use.
  • Brief Description
    AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
  • Description
    AD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Src
  • Recptor
    Src | Bcr-Abl
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1093380-42-7
  • Formula Weight
    455.44
  • Molecular Formula
    C22H20F3N7O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (274.46 mM; Ultrasonic )
  • SMILES
    CC(C)n1nc(-c2ccc(NC(=O)Nc3cccc(c3)C(F)(F)F)cc2)c2c(N)ncnc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Dar AC, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012 Jun 6;486(7401):80-4. ?
molnova catalog
related products
  • CH6953755

    CH6953755 is an orally active, potent and selective YES1 kinase inhibitor (IC50:1.8 nM).CH6953755 has anticancer activity and inhibits cancer cell proliferation by inhibiting YES1 kinase.

  • KX2-361

    KX2-361 (KX 02) is a potent, dual Src signaling/tubulin polymerization inhibitor that are under clinical evaluation.

  • SI-2 hydrochloride

    SI-2 hydrochloride (EPH 116 hydrochloride) is a highly promising inhibitor of SRC-3 SMI: SRC-3 (PPI)(IC50 values of 3-20 nM for breast cancer cell death), with acceptable oral availability.